However, recent studies suggest that MpBCs may express programmed death-ligand 1 (PD-L1) and share molecular features with mesenchymal-like and immune-evasive breast cancer phenotypes, potentially making them candidates for immunotherapy [7]. This evidence concerns the gene CD274 and breast cancer.